Silo Pharma, Inc.
Silo Pharma, Inc. (SILO): 5 pipeline candidates · ~23 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
22.5 months
D/E 0.24 · 0% dilution
Lead: Approved
5 candidates
N/A
N/A
A transparent, data-derived signal for Silo Pharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.3M
Cash
$3.9M
Quarterly Burn
$823K
Runway
22.5 mo
Revenue
$18K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$379K
| Holder | Shares | Value |
|---|---|---|
| advisorshares investments llc | 663,965 | $239K |
| geode capital management, llc | 180,031 | $65K |
| susquehanna international group, llp | 62,795 | $23K |
| jane street group, llc | 44,763 | $16K |
| vanguard capital management llc | 22,442 | $8K |
| citadel advisors llc | 21,448 | $8K |
| xtx topco ltd | 17,083 | $6K |
| two sigma securities, llc | 14,503 | $5K |
| vanguard fiduciary trust co | 13,100 | $5K |
| state street corp | 12,500 | $4K |
Showing top 10 of 14 institutional holders of Silo Pharma, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Silo Pharma, Inc.'s pipeline?
Silo Pharma, Inc. (SILO) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Silo Pharma, Inc.'s lead drug candidate?
Silo Pharma, Inc.'s most advanced tracked candidate is finacea (Approved) for 1 INDICATIONS AND USAGE FINACEA Foam, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. FINACEA Foam is indicated for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea. ( 1 ).
What is Silo Pharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Silo Pharma, Inc. has approximately 22.5 months of cash runway.
What is Silo Pharma, Inc.'s market capitalization?
Silo Pharma, Inc.'s market capitalization is approximately $6.3M.
Who is the CEO of Silo Pharma, Inc.?
Mr. Eric Weisblum is the chief executive officer of Silo Pharma, Inc. (SILO).
Get the full picture on Silo Pharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.